Monday was a good day for HeartWare (Framingham, Massachusetts), a company that develops miniaturized circulatory support technologies for the treatment of heart failure, as it released data Sunday from its pivotal bridge to heart transplantation (BTT) study, ADVANCE. Unfortunately for its primary competitor, Thoratec (Pleasanton, California), its shareholders couldn't say the same. (Medical Device Daily) Read More
